KEROS THERAPEUTICS IN

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

26 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

16 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference

12 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Second Quarter 2024 Financial Results

07 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Leadership Updates

17 Jun 2024 15:01:02 By Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

17 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Host a Corporate Update Conference Call and Webcast

04 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

28 May 2024 15:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association

14 May 2024 09:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

08 May 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

14 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

05 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

28 Feb 2024 15:01:00 By Nasdaq GlobeNewswire

Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

29 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

09 Jan 2024 07:00:00 By Nasdaq GlobeNewswire